Hypocretin/orexin Antagonists Decrease Cocaine Self-administration by Female Rhesus Monkeys
Overview
Authors
Affiliations
Background: The hypocretin/orexin system is involved in regulating arousal, and much recent work demonstrates that decreasing hypocretin receptor-1 (HCRTr1) activity using antagonists decreases appetitive behavior, including stimulant drug self-administration and reinstatement.
Methods: The present study determined the effects of hypocretin-1 and HCRTr1 antagonists on responding reinforced by intravenous (i.v.) cocaine self-administration (0.0125 - 0.05 mg/kg/infusion) in 5 female rhesus monkeys. Responding was examined using 3 schedules of reinforcement: 1) a Fixed interval 1 min, Fixed ratio 10 Chain schedule [FI 1-min (FR10:S)], 2) a Progressive Ratio (PR) schedule, and 3) a cocaine vs. candy.
Results: Choice schedule: the HCRTr1 antagonist SB-334867 (8-24 mg/kg, i.m.) decreased cocaine taking under the Chain schedule and PR schedule in all 5 monkeys and in 4 of the 5 monkeys under the Choice schedule. d- Amphetamine (0.06 - 0.25 mg/kg, i.m.), tested as a control manipulation, decreased cocaine taking in all 5 monkeys under the Chain schedule. The peptide hypocretin-1 (0.072 mg/kg, i.v.) increased cocaine taking in the monkeys with low rates of cocaine taking under the Chain (3/4) and Choice (4/5) schedules. Reinstatement of extinguished cocaine responding following response-independent delivery of a large dose of cocaine (0.3 mg/kg) was attenuated in 3 of the 5 monkeys by the HCRTr1 antagonist SB-334867.
Conclusions: These data expand upon work accomplished in predominantly male rodents suggesting that the hypocretin system modulates the response to appetitive stimuli. A better understanding of this system offers promise as a novel approach in medication development for appetitive disorders.
The Role of Orexin Receptor Antagonists in Inhibiting Drug Addiction: A Review Article.
Esmaili-Shahzade-Ali-Akbari P, Ghaderi A, Sadeghi A, Nejat F, Mehramiz A Addict Health. 2024; 16(2):130-139.
PMID: 39051042 PMC: 11264478. DOI: 10.34172/ahj.2024.1491.
Illenberger J, Flores-Ramirez F, Pascasio G, Franco M, Mendonsa B, Martin-Fardon R J Psychopharmacol. 2024; 38(7):647-660.
PMID: 38888086 PMC: 11407285. DOI: 10.1177/02698811241260989.
Hypocretin (Orexin) Replacement Therapies.
Seigneur E, De Lecea L Med Drug Discov. 2024; 8.
PMID: 38738170 PMC: 11086741. DOI: 10.1016/j.medidd.2020.100070.
Strickland J, Hatton K, Hays L, Rayapati A, Lile J, Rush C Behav Pharmacol. 2023; 34(5):275-286.
PMID: 37403694 PMC: 10328554. DOI: 10.1097/FBP.0000000000000731.
Illenberger J, Flores-Ramirez F, Matzeu A, Mason B, Martin-Fardon R Front Pharmacol. 2023; 14:1127735.
PMID: 37180716 PMC: 10172671. DOI: 10.3389/fphar.2023.1127735.